These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 12639085)

  • 41. [Pathophysiology of sepsis and possible influence of statins].
    Fraunberger P; Drexel H; Walli AK
    Dtsch Med Wochenschr; 2010 Oct; 135(43):2128-32. PubMed ID: 20960384
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lack of evidence for qualitative treatment by disease severity interactions in clinical studies of severe sepsis.
    Macias WL; Nelson DR; Williams M; Garg R; Janes J; Sashegyi A
    Crit Care; 2005; 9(6):R607-22. PubMed ID: 16280057
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antithrombin replacement in patients with sepsis and septic shock.
    Giudici D; Baudo F; Palareti G; Ravizza A; Ridolfi L; D' Angelo A
    Haematologica; 1999 May; 84(5):452-60. PubMed ID: 10329925
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Sepsis in adults and foals.
    Roy MF
    Vet Clin North Am Equine Pract; 2004 Apr; 20(1):41-61. PubMed ID: 15062458
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [[Antithrombin III concentrates in the treatmetn of sepsis and septic shock: indictions, limits and future prospects] ].
    Baudo F; de Cataldo F
    Minerva Anestesiol; 2000 Nov; 66(11 Suppl 1):3-23. PubMed ID: 11213542
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of empirical treatment with moxifloxacin and meropenem vs meropenem on sepsis-related organ dysfunction in patients with severe sepsis: a randomized trial.
    Brunkhorst FM; Oppert M; Marx G; Bloos F; Ludewig K; Putensen C; Nierhaus A; Jaschinski U; Meier-Hellmann A; Weyland A; Gründling M; Moerer O; Riessen R; Seibel A; Ragaller M; Büchler MW; John S; Bach F; Spies C; Reill L; Fritz H; Kiehntopf M; Kuhnt E; Bogatsch H; Engel C; Loeffler M; Kollef MH; Reinhart K; Welte T;
    JAMA; 2012 Jun; 307(22):2390-9. PubMed ID: 22692171
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Advances in the understanding of clinical manifestations and therapy of severe sepsis: an update for critical care nurses.
    Ely EW; Kleinpell RM; Goyette RE
    Am J Crit Care; 2003 Mar; 12(2):120-33; quiz 134-5. PubMed ID: 12625170
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Benefit-risk assessment of drotrecogin alfa (activated) in the treatment of sepsis.
    De Backer D
    Drug Saf; 2007; 30(11):995-1010. PubMed ID: 17973539
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacological management of pediatric patients with sepsis.
    Simmons ML; Durham SH; Carter CW
    AACN Adv Crit Care; 2012; 23(4):437-48; quiz 449-50. PubMed ID: 23095969
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mediator-specific therapies for the systemic inflammatory response syndrome, sepsis, severe sepsis, and septic shock: present and future approaches.
    Hazinski MF
    Crit Care Nurs Clin North Am; 1994 Jun; 6(2):309-19. PubMed ID: 7946190
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Non-antibiotic strategies for sepsis.
    Cohen J
    Clin Microbiol Infect; 2009 Apr; 15(4):302-7. PubMed ID: 19416301
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Gram-negative bacterial sepsis and sepsis syndrome.
    Dunn DL
    Surg Clin North Am; 1994 Jun; 74(3):621-35. PubMed ID: 8197534
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Blood and plasma treatments: high-volume hemofiltration--a global view.
    Honoré PM; Joannes-Boyau O; Gressens B
    Contrib Nephrol; 2007; 156():371-86. PubMed ID: 17464148
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sepsis and septic shock.
    Zanetti G; Baumgartner JD; Glauser MP
    Schweiz Med Wochenschr; 1997 Mar; 127(12):489-99. PubMed ID: 9106949
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Host innate immune responses to microbial pathogens.
    Delaloye J; Calandra T
    Curr Vasc Pharmacol; 2013 Mar; 11(2):123-32. PubMed ID: 23506491
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Meta-analysis: intravenous immunoglobulin in critically ill adult patients with sepsis.
    Turgeon AF; Hutton B; Fergusson DA; McIntyre L; Tinmouth AA; Cameron DW; Hébert PC
    Ann Intern Med; 2007 Feb; 146(3):193-203. PubMed ID: 17283351
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Has mortality from sepsis improved and what to expect from new treatment modalities: review of current insights.
    van Ruler O; Schultz MJ; Reitsma JB; Gouma DJ; Boermeester MA
    Surg Infect (Larchmt); 2009 Aug; 10(4):339-48. PubMed ID: 19673598
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Defects in innate and adaptive immunity in patients with sepsis and health care associated infection.
    Ryan T; Coakley JD; Martin-Loeches I
    Ann Transl Med; 2017 Nov; 5(22):447. PubMed ID: 29264364
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Empty SV40 capsids increase survival of septic rats by eliciting numerous host signaling networks that participate in a number of systemic functions.
    Ben-Nun-Shaul O; Srivastava R; Elgavish S; Gandhi S; Nevo Y; Benyamini H; Eden A; Oppenheim A
    Oncotarget; 2020 Feb; 11(6):574-588. PubMed ID: 32110278
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Animal and human models for sepsis.
    Schultz MJ; van der Poll T
    Ann Med; 2002; 34(7-8):573-81. PubMed ID: 12553497
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.